



PHARMACEUTICALS

As a field of technology, pharmaceuticals involves the discovery, development, manufacture, and delivery of therapeutic, diagnostic, and prognostic agents for treating and preventing diseases. New products are constantly being discovered that enhance the quality of life, including small molecule drugs and biopharmaceuticals, such as recombinant proteins (i.e., antibodies), vaccines, and antisense nucleic acids.

Our firm's attorneys have extensive experience with, for example:

- Antipyretics
- Analgesics
- Antimalarial drugs
- Antibiotics
- Antiseptics
- Mood stabilizers
- Hormone replacements
- Oral contraceptives
- Stimulants
- Tranquilizers
- Statins

Our professionals have academic and advanced degrees in cell and development biology, molecular and cellular biology, biological and computational chemistry, organic chemistry, chemical engineering, medical technology, physiology and biophysics, and epidemiology and biostatistics. In the area of pharmaceuticals, many attorneys at Hamilton Brook Smith Reynolds have Ph.D. degrees.

We seek to assist our clients in realizing their many overall business goals through innovative and careful approaches to patent prosecution, complex litigation, and transactions relating to pharmaceuticals. We excel at counseling biotechnology and chemical companies in the preparation and maintenance of their patent portfolio to maximize the value and utility of their intellectual property portfolio. Other services include:

- Patent prosecution from filing to issue
- Freedom-to-operate opinions
- Patent interferences
- Patent term extensions
- Orange Book listing strategies
- Due diligence
- Post-grant proceedings
- FDA filings for drug approval
- Representation and advice in Abbreviated New Drug
- Application (ANDA) litigation and infringement actions

Examples of our experience in pharmaceuticals are assisting in the patenting of anti-malarial compounds, diastereomers of a small molecule compound effective for treating ischemia-reperfusion injury, and antisense nucleic acids targeting micro RNAs that are overexpressed in cancer.

